Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections

DOI record: { "DOI": "10.1007/s11095-023-03520-1", "ISSN": [ "0724-8741", "1573-904X" ], "URL": "http://dx.doi.org/10.1007/s11095-023-03520-1", "alternative-id": [ "3520" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "5 January 2023" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "10 April 2023" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "25 April 2023" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare no conflict of interest to this review." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Loo", "given": "Ching-Yee", "sequence": "first" }, { "affiliation": [], "family": "Lee", "given": "Wing-Hin", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-1438-6990", "affiliation": [], "authenticated-orcid": false, "family": "Zhou", "given": "Qi Tony", "sequence": "additional" } ], "container-title": "Pharmaceutical Research", "container-title-short": "Pharm Res", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2023, 4, 25 ] ], "date-time": "2023-04-25T20:27:25Z", "timestamp": 1682454445000 }, "deposited": { "date-parts": [ [ 2023, 4, 25 ] ], "date-time": "2023-04-25T21:03:05Z", "timestamp": 1682456585000 }, "funder": [ { "DOI": "10.13039/100006492", "award": [ "R01AI146160" ], "doi-asserted-by": "publisher", "name": "Division of Intramural Research, National Institute of Allergy and Infectious Diseases" } ], "indexed": { "date-parts": [ [ 2023, 4, 26 ] ], "date-time": "2023-04-26T05:05:39Z", "timestamp": 1682485539097 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 4, 25 ] ] }, "language": "en", "license": [ { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 4, 25 ] ], "date-time": "2023-04-25T00:00:00Z", "timestamp": 1682380800000 } }, { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 4, 25 ] ], "date-time": "2023-04-25T00:00:00Z", "timestamp": 1682380800000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s11095-023-03520-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s11095-023-03520-1/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s11095-023-03520-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2023, 4, 25 ] ] }, "published-online": { "date-parts": [ [ 2023, 4, 25 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.eclinm.2021.100986", "author": "X Jin", "doi-asserted-by": "publisher", "first-page": "100986", "journal-title": "EClinicalMedicine", "key": "3520_CR1", "unstructured": "Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, Zhang J, Wang X, Wang G. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021;37:100986.", "volume": "37", "year": "2021" }, { "DOI": "10.1177/1178636118758651", "author": "D Assane", "doi-asserted-by": "publisher", "first-page": "117863611875865", "journal-title": "Microbiol Insights", "key": "3520_CR2", "unstructured": "Assane D, Makhtar C, Abdoulaye D, Amary F, Djibril B, Amadou D, Niokhor DJB, Amadou D, Cheikh L, Ndongo D, Mbayame N, Lamine F, Bouh BCS. Viral and Bacterial Etiologies of Acute Respiratory Infections Among Children Under 5 Years in Senegal. Microbiol Insights. 2018;11:1178636118758651.", "volume": "11", "year": "2018" }, { "DOI": "10.1155/2021/6741290", "author": "M Ftouh", "doi-asserted-by": "publisher", "first-page": "6741290", "journal-title": "PPAR Res", "key": "3520_CR3", "unstructured": "Ftouh M, Kalboussi N, Abid N, Sfar S, Mignet N, Bahloul B. Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. PPAR Res. 2021;2021:6741290.", "volume": "2021", "year": "2021" }, { "DOI": "10.1016/j.jconrel.2022.03.051", "author": "D Baldassi", "doi-asserted-by": "publisher", "first-page": "661", "journal-title": "J Control Release", "key": "3520_CR4", "unstructured": "Baldassi D, Ambike S, Feuerherd M, Cheng CC, Peeler DJ, Feldmann DP, Porras-Gonzalez DL, Wei X, Keller LA, Kneidinger N, Stoleriu MG, Popp A, Burgstaller G, Pun SH, Michler T, Merkel OM. Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes. J Control Release. 2022;345:661–74.", "volume": "345", "year": "2022" }, { "DOI": "10.1073/pnas.2024998118", "doi-asserted-by": "crossref", "key": "3520_CR5", "unstructured": "Dong C, Wang Y, Gonzalez GX, Ma Y, Song Y, Wang S, Kang SM, Compans RW, Wang BZ. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains. Proc Natl Acad Sci USA. 2021;118(19):e2024998118." }, { "DOI": "10.1056/NEJMoa2034577", "author": "FP Polack", "doi-asserted-by": "publisher", "first-page": "2603", "issue": "27", "journal-title": "N Engl J Med", "key": "3520_CR6", "unstructured": "Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.", "volume": "383", "year": "2020" }, { "DOI": "10.1056/NEJMoa2035389", "author": "LR Baden", "doi-asserted-by": "publisher", "first-page": "403", "issue": "5", "journal-title": "N Engl J Med", "key": "3520_CR7", "unstructured": "Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020;384(5):403–16.", "volume": "384", "year": "2020" }, { "DOI": "10.3390/ph14101059", "doi-asserted-by": "crossref", "key": "3520_CR8", "unstructured": "Tulbah AS, Lee WH. Physicochemical characteristics and in vitro toxicity/Anti-SARS-CoV-2 activity of Favipiravir solid lipid nanoparticles (SLNs). Pharmaceuticals (Basel, Switzerland). 2021;14(10):1059." }, { "DOI": "10.3390/pharmaceutics12111002", "doi-asserted-by": "crossref", "key": "3520_CR9", "unstructured": "Sahakijpijarn S, Moon C, Koleng JJ, Christensen DJ, Williams Iii RO. Development of remdesivir as a dry powder for inhalation by Thin Film Freezing. Pharmaceutics. 2020;12(11):1002." }, { "DOI": "10.1053/rmed.2002.1457", "author": "DA Groneberg", "doi-asserted-by": "publisher", "first-page": "382", "issue": "4", "journal-title": "Respir Med", "key": "3520_CR10", "unstructured": "Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir Med. 2003;97(4):382–7.", "volume": "97", "year": "2003" }, { "DOI": "10.2217/nnm-2021-0447", "author": "CY Loo", "doi-asserted-by": "publisher", "first-page": "865", "issue": "12", "journal-title": "Nanomedicine (Lond)", "key": "3520_CR11", "unstructured": "Loo CY, Lee WH. Nanotechnology-based therapeutics for targeting inflammatory lung diseases. Nanomedicine (Lond). 2022;17(12):865–79.", "volume": "17", "year": "2022" }, { "DOI": "10.1016/j.rmed.2020.105987", "author": "A Ari", "doi-asserted-by": "publisher", "first-page": "105987", "journal-title": "Respir Med", "key": "3520_CR12", "unstructured": "Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020;167:105987.", "volume": "167", "year": "2020" }, { "DOI": "10.1016/B978-0-12-386454-3.00099-3", "author": "GM Fent", "doi-asserted-by": "publisher", "edition": "3", "first-page": "342", "key": "3520_CR13", "unstructured": "Fent GM. Avermectin. In: Wexler P, editor. Encyclopedia of Toxicology. 3rd ed. Oxford: Academic Press; 2014. p. 342–4.", "volume-title": "Encyclopedia of Toxicology", "year": "2014" }, { "DOI": "10.1016/j.jics.2021.100262", "author": "SS Kapale", "doi-asserted-by": "publisher", "first-page": "100262", "issue": "12", "journal-title": "J Indian Chem Soc", "key": "3520_CR14", "unstructured": "Kapale SS, Chaudhari HK. Niclosamide & challenges in chemical modifications: A broad review on enhancement of solubility. J Indian Chem Soc. 2021;98(12):100262.", "volume": "98", "year": "2021" }, { "DOI": "10.3390/pharmaceutics13081260", "doi-asserted-by": "crossref", "key": "3520_CR15", "unstructured": "Tai W, Chow MY, Chang RY, Tang P, Gonda I, MacArthur RB, Chan H-K, Kwok PC. Nebulised isotonic hydroxychloroquine aerosols for potential treatment of COVID-19. Pharmaceutics. 2021;13(8):1260." }, { "DOI": "10.1021/acsnano.0c04006", "author": "G Chauhan", "doi-asserted-by": "publisher", "first-page": "7760", "issue": "7", "journal-title": "ACS Nano", "key": "3520_CR16", "unstructured": "Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano. 2020;14(7):7760–82.", "volume": "14", "year": "2020" }, { "DOI": "10.1016/j.jpba.2021.114482", "author": "B Várnai", "doi-asserted-by": "publisher", "first-page": "114482", "journal-title": "J Pharm Biomed Anal", "key": "3520_CR17", "unstructured": "Várnai B, Malanga M, Sohajda T, Béni S. Molecular interactions in remdesivir-cyclodextrin systems. J Pharm Biomed Anal. 2022;209:114482.", "volume": "209", "year": "2022" }, { "DOI": "10.1021/jm900080g", "author": "DA DeGoey", "doi-asserted-by": "publisher", "first-page": "2964", "issue": "9", "journal-title": "J Med Chem", "key": "3520_CR18", "unstructured": "DeGoey DA, Grampovnik DJ, Flosi WJ, Marsh KC, Wang XC, Klein LL, McDaniel KF, Liu Y, Long MA, Kati WM, Molla A, Kempf DJ. Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir. J Med Chem. 2009;52(9):2964–70.", "volume": "52", "year": "2009" }, { "DOI": "10.1016/j.xphs.2016.01.017", "author": "N Goodarzi", "doi-asserted-by": "publisher", "first-page": "1362", "issue": "4", "journal-title": "J Pharm Sci", "key": "3520_CR19", "unstructured": "Goodarzi N, Barazesh Morgani A, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, Polli JE, Shah VP, Dressman JB. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. J Pharm Sci. 2016;105(4):1362–9.", "volume": "105", "year": "2016" }, { "DOI": "10.1038/s41564-020-0688-y", "author": "M Letko", "doi-asserted-by": "publisher", "first-page": "562", "issue": "4", "journal-title": "Nat Microbiol", "key": "3520_CR20", "unstructured": "Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–9.", "volume": "5", "year": "2020" }, { "DOI": "10.1038/s41580-021-00418-x", "author": "CB Jackson", "doi-asserted-by": "publisher", "first-page": "3", "issue": "1", "journal-title": "Nat Rev Mol Cell Biol", "key": "3520_CR21", "unstructured": "Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.", "volume": "23", "year": "2022" }, { "DOI": "10.1016/S1473-3099(21)00396-0", "author": "S Wu", "doi-asserted-by": "publisher", "first-page": "1654", "issue": "12", "journal-title": "Lancet Infect Dis", "key": "3520_CR22", "unstructured": "Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, Wang B, Chen C, Chen Y, Song X, Wang Y, Si W, Sun T, Wang X, Hou L, Chen W. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654–64.", "volume": "21", "year": "2021" }, { "DOI": "10.1016/S2213-2600(22)00087-X", "author": "JX Li", "doi-asserted-by": "publisher", "first-page": "739", "issue": "8", "journal-title": "Lancet Respir Med", "key": "3520_CR23", "unstructured": "Li JX, Wu SP, Guo XL, Tang R, Huang BY, Chen XQ, Chen Y, Hou LH, Liu JX, Zhong J, Pan HX, Shi FJ, Xu XY, Li ZP, Zhang XY, Cui LB, Tan WJ, Chen W, Zhu FC. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–48.", "volume": "10", "year": "2022" }, { "DOI": "10.1126/science.abe3255", "author": "M Schoof", "doi-asserted-by": "publisher", "first-page": "1473", "issue": "6523", "journal-title": "Science (New York, NY)", "key": "3520_CR24", "unstructured": "Schoof M, Faust B, Saunders RA, Sangwan S, Rezelj V, Hoppe N, Boone M, Billesbølle CB, Puchades C, Azumaya CM, Kratochvil HT, Zimanyi M, Deshpande I, Liang J, Dickinson S, Nguyen HC, Chio CM, Merz GE, Thompson MC, Diwanji D, Schaefer K, Anand AA, Dobzinski N, Zha BS, Simoneau CR, Leon K, White KM, Chio US, Gupta M, Jin M, Li F, Liu Y, Zhang K, Bulkley D, Sun M, Smith AM, Rizo AN, Moss F, Brilot AF, Pourmal S, Trenker R, Pospiech T, Gupta S, Barsi-Rhyne B, Belyy V, Barile-Hill AW, Nock S, Liu Y, Krogan NJ, Ralston CY, Swaney DL, García-Sastre A, Ott M, Vignuzzi M, Walter P, Manglik A. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science (New York, NY). 2020;370(6523):1473–9.", "volume": "370", "year": "2020" }, { "DOI": "10.1126/sciadv.abh0319", "doi-asserted-by": "crossref", "key": "3520_CR25", "unstructured": "Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y, Duprex WP. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. 2021;7(22): eabh0319." }, { "DOI": "10.1080/19420862.2022.2047144", "author": "TJ Esparza", "doi-asserted-by": "publisher", "first-page": "2047144", "issue": "1", "journal-title": "MAbs", "key": "3520_CR26", "unstructured": "Esparza TJ, Chen Y, Martin NP, Bielefeldt-Ohmann H, Bowen RA, Tolbert WD, Pazgier M, Brody DL. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. MAbs. 2022;14(1):2047144.", "volume": "14", "year": "2022" }, { "DOI": "10.1002/mco2.60", "doi-asserted-by": "crossref", "key": "3520_CR27", "unstructured": "Gai J, Ma L, Li G, Zhu M, Qiao P, Li X, Zhang H, Zhang Y, Chen Y, Ji W, Zhang H, Cao H, Li X, Gong R, Wan Y. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm (2020). 2021;2(1):101–13." }, { "DOI": "10.1038/s41467-021-25480-z", "author": "J Huo", "doi-asserted-by": "publisher", "first-page": "5469", "issue": "1", "journal-title": "Nat Commun", "key": "3520_CR28", "unstructured": "Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, Moynié L, Ward PN, Dumoux M, Prince T, Hall Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, Owens RJ. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun. 2021;12(1):5469.", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.cell.2022.03.009", "author": "C Li", "doi-asserted-by": "publisher", "first-page": "1389", "issue": "8", "journal-title": "Cell", "key": "3520_CR29", "unstructured": "Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X, Song W, Du S, Zhu Y, Huang K, Kong Y, Zhang M, Mao Q, Gu X, Zhang Y, Xie Y, Deng Q, Song Y, Chen Z, Lu L, Jiang S, Wu Y, Sun L, Ying T. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022;185(8):1389-1401.e1318.", "volume": "185", "year": "2022" }, { "DOI": "10.1016/j.isci.2021.103479", "author": "S Ndeupen", "doi-asserted-by": "publisher", "first-page": "103479", "issue": "12", "journal-title": "iScience.", "key": "3520_CR30", "unstructured": "Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyártó BZ. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479.", "volume": "24", "year": "2021" }, { "DOI": "10.1101/2022.03.22.485401", "doi-asserted-by": "crossref", "key": "3520_CR31", "unstructured": "Suberi A, Grun MK, Mao T, Israelow B, Reschke M, Grundler J, Akhtar L, Lee T, Shin K, Piotrowski-Daspit AS, Homer RJ, Iwasaki A, Suh HW, Saltzman WM. Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccination. bioRxiv. 2022." }, { "DOI": "10.1016/j.matt.2021.09.022", "author": "Z Wang", "doi-asserted-by": "publisher", "first-page": "336", "issue": "1", "journal-title": "Matter", "key": "3520_CR32", "unstructured": "Wang Z, Xiang L, Lin F, Cai Z, Ruan H, Wang J, Liang J, Wang F, Lu M, Cui W. Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm. Matter. 2022;5(1):336–62.", "volume": "5", "year": "2022" }, { "DOI": "10.1111/all.14850", "author": "M Khaitov", "doi-asserted-by": "publisher", "first-page": "2840", "issue": "9", "journal-title": "Allergy", "key": "3520_CR33", "unstructured": "Khaitov M, Nikonova A, Shilovskiy I, Kozhikhova K, Kofiadi I, Vishnyakova L, Nikolskii A, Gattinger P, Kovchina V, Barvinskaia E, Yumashev K, Smirnov V, Maerle A, Kozlov I, Shatilov A, Timofeeva A, Andreev S, Koloskova O, Kuznetsova N, Vasina D, Nikiforova M, Rybalkin S, Sergeev I, Trofimov D, Martynov A, Berzin I, Gushchin V, Kovalchuk A, Borisevich S, Valenta R, Khaitov R, Skvortsova V. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. 2021;76(9):2840–54.", "volume": "76", "year": "2021" }, { "DOI": "10.1016/j.cegh.2020.07.011", "author": "A Frediansyah", "doi-asserted-by": "publisher", "first-page": "123", "journal-title": "Clinical epidemiology and global health", "key": "3520_CR34", "unstructured": "Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical epidemiology and global health. 2021;9:123–7.", "volume": "9", "year": "2021" }, { "DOI": "10.1021/acs.jmedchem.6b01594", "author": "D Siegel", "doi-asserted-by": "publisher", "first-page": "1648", "issue": "5", "journal-title": "J Med Chem", "key": "3520_CR35", "unstructured": "Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017;60(5):1648–61.", "volume": "60", "year": "2017" }, { "DOI": "10.1073/pnas.2012294117", "author": "MK Lo", "doi-asserted-by": "publisher", "first-page": "26946", "issue": "43", "journal-title": "Proc Natl Acad Sci", "key": "3520_CR36", "unstructured": "Lo MK, Albariño CG, Perry JK, Chang S, Tchesnokov EP, Guerrero L, Chakrabarti A, Shrivastava-Ranjan P, Chatterjee P, McMullan LK, Martin R, Jordan R, Götte M, Montgomery JM, Nichol ST, Flint M, Porter D, Spiropoulou CF. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc Natl Acad Sci. 2020;117(43):26946–54.", "volume": "117", "year": "2020" }, { "DOI": "10.1073/pnas.1922083117", "author": "E de Wit", "doi-asserted-by": "publisher", "first-page": "6771", "issue": "12", "journal-title": "Proc Natl Acad Sci", "key": "3520_CR37", "unstructured": "de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020;117(12):6771–6.", "volume": "117", "year": "2020" }, { "DOI": "10.1038/nature17180", "author": "TK Warren", "doi-asserted-by": "publisher", "first-page": "381", "issue": "7594", "journal-title": "Nature", "key": "3520_CR38", "unstructured": "Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–5.", "volume": "531", "year": "2016" }, { "DOI": "10.1126/scitranslmed.aal3653", "doi-asserted-by": "crossref", "key": "3520_CR39", "unstructured": "Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653." }, { "author": "S Sahakijpijarn", "first-page": "100073", "journal-title": "Int J Pharm X", "key": "3520_CR40", "unstructured": "Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen DJ, Koleng JJ, Williams RO 3rd. In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters. Int J Pharm X. 2021;3:100073.", "volume": "3", "year": "2021" }, { "DOI": "10.2217/nnm-2020-0475", "author": "R Vartak", "doi-asserted-by": "publisher", "first-page": "1187", "issue": "14", "journal-title": "Nanomedicine (Lond)", "key": "3520_CR41", "unstructured": "Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine (Lond). 2021;16(14):1187–202.", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.ajps.2021.09.002", "author": "J Li", "doi-asserted-by": "publisher", "first-page": "772", "issue": "6", "journal-title": "Asian J Pharm Sci", "key": "3520_CR42", "unstructured": "Li J, Zhang K, Wu D, Ren L, Chu X, Qin C, Han X, Hang T, Xu Y, Yang L, Yin L. Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19. Asian J Pharm Sci. 2021;16(6):772–83.", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.jddst.2022.103625", "author": "E Halevas", "doi-asserted-by": "publisher", "first-page": "103625", "journal-title": "J Drug Deliv Sci Technol", "key": "3520_CR43", "unstructured": "Halevas E, Mavroidi B, Kokotidou C, Moschona A, Sagnou M, Mitraki A, Litsardakis G, Pelecanou M. Remdesivir-loaded bis-MPA hyperbranched dendritic nanocarriers for pulmonary delivery. J Drug Deliv Sci Technol. 2022;75:103625.", "volume": "75", "year": "2022" }, { "DOI": "10.1111/cts.12797", "author": "SLM Arnold", "doi-asserted-by": "publisher", "first-page": "642", "issue": "4", "journal-title": "Clin Transl Sci", "key": "3520_CR44", "unstructured": "Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. Clin Transl Sci. 2020;13(4):642–5.", "volume": "13", "year": "2020" }, { "DOI": "10.1038/s41591-020-0888-2", "author": "E Chorin", "doi-asserted-by": "publisher", "first-page": "808", "issue": "6", "journal-title": "Nat Med", "key": "3520_CR45", "unstructured": "Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–9.", "volume": "26", "year": "2020" }, { "DOI": "10.1111/bph.15167", "author": "SC Fassihi", "doi-asserted-by": "publisher", "first-page": "4997", "issue": "21", "journal-title": "Br J Pharmacol", "key": "3520_CR46", "unstructured": "Fassihi SC, Nabar NR, Fassihi R. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19. Br J Pharmacol. 2020;177(21):4997–8.", "volume": "177", "year": "2020" }, { "DOI": "10.1016/j.mehy.2020.109783", "author": "A Klimke", "doi-asserted-by": "publisher", "first-page": "109783", "journal-title": "Med Hypotheses", "key": "3520_CR47", "unstructured": "Klimke A, Hefner G, Will B, Voss U. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. Med Hypotheses. 2020;142:109783.", "volume": "142", "year": "2020" }, { "DOI": "10.1111/cts.12923", "author": "TT Tai", "doi-asserted-by": "publisher", "first-page": "132", "issue": "1", "journal-title": "Clin Transl Sci", "key": "3520_CR48", "unstructured": "Tai TT, Wu TJ, Wu HD, Tsai YC, Wang HT, Wang AM, Shih SF, Chen YC. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study. Clin Transl Sci. 2021;14(1):132–6.", "volume": "14", "year": "2021" }, { "DOI": "10.1089/jamp.2020.1648", "author": "AH Albariqi", "doi-asserted-by": "publisher", "first-page": "20", "issue": "1", "journal-title": "J Aerosol Med Pulm Drug Deliv", "key": "3520_CR49", "unstructured": "Albariqi AH, Chang RYK, Tai W, Ke W-R, Chow MYT, Tang P, Kwok PCL, Chan H-K. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. J Aerosol Med Pulm Drug Deliv. 2020;34(1):20–31.", "volume": "34", "year": "2020" }, { "DOI": "10.1371/journal.pone.0272034", "author": "YA de Reus", "doi-asserted-by": "publisher", "first-page": "e0272034", "issue": "8", "journal-title": "PLoS ONE", "key": "3520_CR50", "unstructured": "de Reus YA, Hagedoorn P, Sturkenboom MGG, Grasmeijer F, Bolhuis MS, Sibum I, Kerstjens HAM, Frijlink HW, Akkerman OW. Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. PLoS ONE. 2022;17(8):e0272034.", "volume": "17", "year": "2022" }, { "DOI": "10.3390/polym14132616", "doi-asserted-by": "crossref", "key": "3520_CR51", "unstructured": "Ali AS, Alrashedi MG, Ahmed OAA, Ibrahim IM. Pulmonary delivery of hydroxychloroquine nanostructured lipid carrier as a potential treatment of COVID-19. Polymers (Basel). 2022;14(13):2616." }, { "DOI": "10.1007/s40097-022-00476-3", "doi-asserted-by": "crossref", "key": "3520_CR52", "unstructured": "de Barros AOdS, Pinto SR, dos Reis SRR, Ricci-Junior E, Alencar LMR, Bellei NCJ, Janini LRM, Maricato JT, Rosa DS, Santos-Oliveira R. Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect. J Nanostruct Chem. 2022;13(2):263–81." }, { "DOI": "10.3390/covid2080078", "doi-asserted-by": "crossref", "key": "3520_CR53", "unstructured": "Corritori S, Savchuk N, Pauza CD. Risk/benefit profiles of currently approved oral antivirals for treatment of COVID-19: similarities and differences. COVID. 2022;2(8):1057–76." }, { "DOI": "10.1371/journal.pntd.0006034", "author": "P Chinello", "doi-asserted-by": "publisher", "first-page": "e0006034", "issue": "12", "journal-title": "PLOS Negl Trop Dis", "key": "3520_CR54", "unstructured": "Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E, on behalf of the IET. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLOS Negl Trop Dis. 2017;11(12):e0006034.", "volume": "11", "year": "2017" }, { "DOI": "10.3390/pharmaceutics14112375", "doi-asserted-by": "crossref", "key": "3520_CR55", "unstructured": "Akbal-Dagistan O, Sevim M, Sen LS, Basarir NS, Culha M, Erturk A, Fael H, Kaptan E, Sancar S, Mulazimoglu Durmusoglu L, Yegen BC, Yildiz-Pekoz A. Pulmonary delivery of favipiravir in rats reaches high local concentrations without causing oxidative lung injury or systemic side effects. Pharmaceutics. 2022;14(11):2375." }, { "DOI": "10.1080/10717544.2022.2118398", "author": "A Yildiz Pekoz", "doi-asserted-by": "publisher", "first-page": "2846", "issue": "1", "journal-title": "Drug Deliv", "key": "3520_CR56", "unstructured": "Yildiz Pekoz A, Akbal Dagistan O, Fael H, Culha M, Erturk A, Basarir NS, Sahin G, Serhatli M, Cakirca G, Tekin S, Sen LS, Sevim M, Mulazimoglu Durmusoglu L, Yegen BC. Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis. Drug Deliv. 2022;29(1):2846–54.", "volume": "29", "year": "2022" }, { "DOI": "10.1016/j.apsb.2022.01.019", "author": "B Tu", "doi-asserted-by": "publisher", "first-page": "3187", "issue": "7", "journal-title": "Acta Pharm Sin B", "key": "3520_CR57", "unstructured": "Tu B, Wang H, An X, Qu J, Li Q, Gao Y, Shi M, Qiu H, Huang Y. Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. Acta Pharm Sin B. 2022;12(7):3187–94.", "volume": "12", "year": "2022" }, { "DOI": "10.3389/fphar.2020.592238", "author": "H Jin", "doi-asserted-by": "publisher", "first-page": "592238", "journal-title": "Front Pharmacol", "key": "3520_CR58", "unstructured": "Jin H, Zhao Z, Lan Q, Zhou H, Mai Z, Wang Y, Ding X, Zhang W, Pi J, Evans CE, Liu X. Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury. Front Pharmacol. 2020;11:592238.", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.matt.2021.04.005", "author": "M Chen", "doi-asserted-by": "publisher", "first-page": "2059", "issue": "6", "journal-title": "Matter", "key": "3520_CR59", "unstructured": "Chen M, Rosenberg J, Cai X, Lee ACH, Shi J, Nguyen M, Wignakumar T, Mirle V, Edobor AJ, Fung J, Donington JS, Shanmugarajah K, Lin Y, Chang E, Randall G, Penaloza-MacMaster P, Tian B, Madariaga ML, Huang J. Nanotraps for the containment and clearance of SARS-CoV-2. Matter. 2021;4(6):2059–82.", "volume": "4", "year": "2021" }, { "DOI": "10.1038/s41565-021-00923-2", "author": "Z Li", "doi-asserted-by": "publisher", "first-page": "942", "issue": "8", "journal-title": "Nat Nanotechnol", "key": "3520_CR60", "unstructured": "Li Z, Wang Z, Dinh P-UC, Zhu D, Popowski KD, Lutz H, Hu S, Lewis MG, Cook A, Andersen H, Greenhouse J, Pessaint L, Lobo LJ, Cheng K. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. Nat Nanotechnol. 2021;16(8):942–51.", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.ijpharm.2021.121133", "author": "S Ebrahimi", "doi-asserted-by": "publisher", "first-page": "121133", "journal-title": "Int J Pharm", "key": "3520_CR61", "unstructured": "Ebrahimi S, Shamloo A, Alishiri M, Mofrad YM, Akherati F. Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion. Int J Pharm. 2021;609:121133.", "volume": "609", "year": "2021" }, { "DOI": "10.1016/j.ijbiomac.2021.12.073", "author": "NAN Hanafy", "doi-asserted-by": "publisher", "first-page": "101", "journal-title": "Int J Biol Macromol", "key": "3520_CR62", "unstructured": "Hanafy NAN, El-Kemary MA. Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment. Int J Biol Macromol. 2022;198:101–10.", "volume": "198", "year": "2022" }, { "DOI": "10.1016/j.lfs.2020.117627", "author": "M Kandeel", "doi-asserted-by": "publisher", "first-page": "117627", "journal-title": "Life Sci", "key": "3520_CR63", "unstructured": "Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 2020;251:117627.", "volume": "251", "year": "2020" }, { "DOI": "10.1002/advs.202003556", "author": "B Li", "doi-asserted-by": "publisher", "first-page": "2003556", "issue": "13", "journal-title": "Advanced Science", "key": "3520_CR64", "unstructured": "Li B, Wang W, Song W, Zhao Z, Tan Q, Zhao Z, Tang L, Zhu T, Yin J, Bai J, Dong X, Tan S, Hu Q, Tang BZ, Huang X. Antiviral and Anti-Inflammatory Treatment with Multifunctional Alveolar Macrophage-Like Nanoparticles in a Surrogate Mouse Model of COVID-19. Advanced Science. 2021;8(13):2003556.", "volume": "8", "year": "2021" }, { "DOI": "10.1016/j.ijpharm.2021.120701", "author": "MO Jara", "doi-asserted-by": "publisher", "first-page": "120701", "journal-title": "Int J Pharm", "key": "3520_CR65", "unstructured": "Jara MO, Warnken ZN, Sahakijpijarn S, Moon C, Maier EY, Christensen DJ, Koleng JJ, Peters JI, Hackman Maier SD, Williams Iii RO. Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters. Int J Pharm. 2021;603:120701.", "volume": "603", "year": "2021" }, { "DOI": "10.1016/j.ijpharm.2022.121688", "author": "AH Albariqi", "doi-asserted-by": "publisher", "first-page": "121688", "journal-title": "Int J Pharm", "key": "3520_CR66", "unstructured": "Albariqi AH, Wang Y, Chang RYK, Quan DH, Wang X, Kalfas S, Drago J, Britton WJ, Chan HK. Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment. Int J Pharm. 2022;619:121688.", "volume": "619", "year": "2022" }, { "DOI": "10.1016/j.jaci.2020.09.034", "author": "LJ Finney", "doi-asserted-by": "publisher", "first-page": "510", "issue": "2", "journal-title": "J Allergy Clin Immunol", "key": "3520_CR67", "unstructured": "Finney LJ, Glanville N, Farne H, Aniscenko J, Fenwick P, Kemp SV, Trujillo-Torralbo MB, Loo SL, Calderazzo MA, Wedzicha JA, Mallia P, Bartlett NW, Johnston SL, Singanayagam A. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2021;147(2):510-519.e515.", "volume": "147", "year": "2021" }, { "DOI": "10.1016/j.plefa.2022.102426", "author": "C Kocherlakota", "doi-asserted-by": "publisher", "first-page": "102426", "journal-title": "Prostaglandins Leukot Essent Fatty Acids", "key": "3520_CR68", "unstructured": "Kocherlakota C, Nagaraju B, Arjun N, Srinath A, Kothapalli KSD, Brenna JT. Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19. Prostaglandins Leukot Essent Fatty Acids. 2022;179:102426.", "volume": "179", "year": "2022" }, { "DOI": "10.1002/adtp.202100059", "author": "Q Liao", "doi-asserted-by": "publisher", "first-page": "2100059", "issue": "7", "journal-title": "Advanced Therapeutics", "key": "3520_CR69", "unstructured": "Liao Q, Yuan S, Cao J, Tang K, Qiu Y, Seow HC, Man RC-H, Shao Z, Huang Y, Liang R, Chan JF-W, Yuen K-Y, Lam JK-W. Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus. Advanced Therapeutics. 2021;4(7):2100059.", "volume": "4", "year": "2021" }, { "DOI": "10.1016/j.ejpb.2018.10.008", "author": "J Tomar", "doi-asserted-by": "publisher", "first-page": "85", "journal-title": "Eur J Pharm Biopharm", "key": "3520_CR70", "unstructured": "Tomar J, Biel C, de Haan CAM, Rottier PJM, Petrovsky N, Frijlink HW, Huckriede A, Hinrichs WLJ, Peeters B. Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge. Eur J Pharm Biopharm. 2018;133:85–95.", "volume": "133", "year": "2018" }, { "DOI": "10.3390/pharmaceutics12121154", "doi-asserted-by": "crossref", "key": "3520_CR71", "unstructured": "Aziz S, Scherlieβ R, Steckel H. Development of high dose oseltamivir phosphate dry powder for inhalation therapy in viral pneumonia. Pharmaceutics. 2020;12(12):1154." }, { "DOI": "10.1038/s41541-021-00320-9", "author": "JM Luczo", "doi-asserted-by": "publisher", "first-page": "59", "issue": "1", "journal-title": "Npj Vaccines", "key": "3520_CR72", "unstructured": "Luczo JM, Bousse T, Johnson SK, Jones CA, Pearce N, Neiswanger CA, Wang M-X, Miller EA, Petrovsky N, Wentworth DE, Bronshtein V, Papania M, Tompkins SM. Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets. Npj Vaccines. 2021;6(1):59.", "volume": "6", "year": "2021" }, { "DOI": "10.2174/1567201817666200530201820", "author": "H Sahastrabudhe", "doi-asserted-by": "publisher", "first-page": "703", "issue": "8", "journal-title": "Curr Drug Deliv", "key": "3520_CR73", "unstructured": "Sahastrabudhe H, Kenjale P, Pokharkar V. Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler: <i>In-Vitro</i> Characterization and <i>In-Vivo</i> Toxicological Studies. Curr Drug Deliv. 2020;17(8):703–10.", "volume": "17", "year": "2020" }, { "DOI": "10.1080/10717544.2018.1435748", "author": "Y Bhide", "doi-asserted-by": "publisher", "first-page": "533", "issue": "1", "journal-title": "Drug Deliv", "key": "3520_CR74", "unstructured": "Bhide Y, Tomar J, Dong W, de Vries-Idema J, Frijlink HW, Huckriede A, Hinrichs WLJ. Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus. Drug Deliv. 2018;25(1):533–45.", "volume": "25", "year": "2018" }, { "DOI": "10.1016/j.vaccine.2007.10.035", "author": "JP Amorij", "doi-asserted-by": "publisher", "first-page": "8707", "issue": "52", "journal-title": "Vaccine", "key": "3520_CR75", "unstructured": "Amorij JP, Saluja V, Petersen AH, Hinrichs WL, Huckriede A, Frijlink HW. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007;25(52):8707–17.", "volume": "25", "year": "2007" }, { "DOI": "10.3109/10717544.2013.863526", "author": "Y Tang", "doi-asserted-by": "publisher", "first-page": "608", "issue": "5", "journal-title": "Drug Delivery", "key": "3520_CR76", "unstructured": "Tang Y, Zhang H, Lu X, Jiang L, Xi X, Liu J, Zhu J. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. Drug Delivery. 2015;22(5):608–18.", "volume": "22", "year": "2015" }, { "DOI": "10.1021/acsami.1c19192", "author": "C Dong", "doi-asserted-by": "publisher", "first-page": "6331", "issue": "5", "journal-title": "ACS Appl Mater Interfaces", "key": "3520_CR77", "unstructured": "Dong C, Wang Y, Zhu W, Ma Y, Kim J, Wei L, Gonzalez GX, Wang B-Z. Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice. ACS Appl Mater Interfaces. 2022;14(5):6331–42.", "volume": "14", "year": "2022" }, { "DOI": "10.1016/j.vaccine.2015.03.063", "author": "W Tao", "doi-asserted-by": "publisher", "first-page": "2307", "issue": "20", "journal-title": "Vaccine", "key": "3520_CR78", "unstructured": "Tao W, Gill HS. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection. Vaccine. 2015;33(20):2307–15.", "volume": "33", "year": "2015" }, { "DOI": "10.1039/C7RA06477B", "author": "Z Lin", "doi-asserted-by": "publisher", "first-page": "35290", "issue": "56", "journal-title": "RSC Adv", "key": "3520_CR79", "unstructured": "Lin Z, Li Y, Guo M, Xiao M, Wang C, Zhao M, Xu T, Xia Y, Zhu B. Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with zanamivir through p38 and JNK signaling pathways. RSC Adv. 2017;7(56):35290–6.", "volume": "7", "year": "2017" }, { "DOI": "10.1016/j.nano.2021.102438", "author": "J Lim", "doi-asserted-by": "publisher", "first-page": "102438", "journal-title": "Nanomed: Nanotechnol Biol Med", "key": "3520_CR80", "unstructured": "Lim J, Cheong Y, Kim Y-S, Chae W, Hwang BJ, Lee J, Jang YH, Roh YH, Seo S-U, Seong BL. RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform. Nanomed: Nanotechnol Biol Med. 2021;37:102438.", "volume": "37", "year": "2021" }, { "DOI": "10.2147/IJN.S140939", "author": "Y Li", "doi-asserted-by": "publisher", "first-page": "5733", "journal-title": "Int J Nanomedicine", "key": "3520_CR81", "unstructured": "Li Y, Lin Z, Guo M, Xia Y, Zhao M, Wang C, Xu T, Chen T, Zhu B. Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus. Int J Nanomedicine. 2017;12:5733–43.", "volume": "12", "year": "2017" }, { "DOI": "10.1208/s12249-013-0058-7", "author": "C Sawaengsak", "doi-asserted-by": "publisher", "first-page": "317", "issue": "2", "journal-title": "AAPS PharmSciTech", "key": "3520_CR82", "unstructured": "Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N. Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS PharmSciTech. 2014;15(2):317–25.", "volume": "15", "year": "2014" }, { "DOI": "10.3389/fimmu.2018.00934", "author": "S Dhakal", "doi-asserted-by": "publisher", "first-page": "934", "journal-title": "Front Immunol", "key": "3520_CR83", "unstructured": "Dhakal S, Renu S, Ghimire S, Shaan Lakshmanappa Y, Hogshead BT, Feliciano-Ruiz N, Lu F, HogenEsch H, Krakowka S, Lee CW, Renukaradhya GJ. Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs. Front Immunol. 2018;9:934.", "volume": "9", "year": "2018" }, { "DOI": "10.1128/JVI.00841-21", "author": "SA Nelson", "doi-asserted-by": "publisher", "first-page": "e0084121", "issue": "16", "journal-title": "J Virol", "key": "3520_CR84", "unstructured": "Nelson SA, Dileepan T, Rasley A, Jenkins MK, Fischer NO, Sant AJ. Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge. J Virol. 2021;95(16):e0084121.", "volume": "95", "year": "2021" }, { "DOI": "10.2217/nnm.13.58", "author": "W Tao", "doi-asserted-by": "publisher", "first-page": "237", "issue": "2", "journal-title": "Nanomedicine (Lond)", "key": "3520_CR85", "unstructured": "Tao W, Ziemer KS, Gill HS. Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (Lond). 2014;9(2):237–51.", "volume": "9", "year": "2014" }, { "DOI": "10.1186/s13567-020-00762-4", "author": "IA Hajam", "doi-asserted-by": "publisher", "first-page": "37", "issue": "1", "journal-title": "Vet Res", "key": "3520_CR86", "unstructured": "Hajam IA, Senevirathne A, Hewawaduge C, Kim J, Lee JH. Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens. Vet Res. 2020;51(1):37.", "volume": "51", "year": "2020" }, { "DOI": "10.1016/j.omtn.2020.04.015", "author": "L Van Hoecke", "doi-asserted-by": "publisher", "first-page": "777", "journal-title": "Mol Therapy Nucleic Acids", "key": "3520_CR87", "unstructured": "Van Hoecke L, Verbeke R, De Vlieger D, Dewitte H, Roose K, Van Nevel S, Krysko O, Bachert C, Schepens B, Lentacker I, Saelens X. mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice. Mol Therapy Nucleic Acids. 2020;20:777–87.", "volume": "20", "year": "2020" }, { "DOI": "10.1038/s41551-021-00786-x", "author": "MP Lokugamage", "doi-asserted-by": "publisher", "first-page": "1059", "issue": "9", "journal-title": "Nat Biomed Eng", "key": "3520_CR88", "unstructured": "Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES, Peck HE, Ni H, Yoon J-K, Kim Y, Santangelo PJ, Dahlman JE. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021;5(9):1059–68.", "volume": "5", "year": "2021" }, { "DOI": "10.1016/j.nano.2018.03.007", "author": "C Wang", "doi-asserted-by": "publisher", "first-page": "1349", "issue": "4", "journal-title": "Nanomedicine", "key": "3520_CR89", "unstructured": "Wang C, Zhu W, Luo Y, Wang BZ. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. Nanomedicine. 2018;14(4):1349–60.", "volume": "14", "year": "2018" }, { "DOI": "10.2147/IJN.S137222", "author": "C Wang", "doi-asserted-by": "publisher", "first-page": "4747", "journal-title": "Int J Nanomedicine", "key": "3520_CR90", "unstructured": "Wang C, Zhu W, Wang BZ. Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro. Int J Nanomedicine. 2017;12:4747–62.", "volume": "12", "year": "2017" }, { "DOI": "10.4049/jimmunol.1202654", "author": "T Knuschke", "doi-asserted-by": "publisher", "first-page": "6221", "issue": "12", "journal-title": "J Immunol", "key": "3520_CR91", "unstructured": "Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli P, Epple M, Buer J, Westendorf AM. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol. 2013;190(12):6221–9.", "volume": "190", "year": "2013" }, { "DOI": "10.1016/j.nano.2017.08.001", "author": "A Frede", "doi-asserted-by": "publisher", "first-page": "2395", "issue": "8", "journal-title": "Nanomedicine", "key": "3520_CR92", "unstructured": "Frede A, Neuhaus B, Knuschke T, Wadwa M, Kollenda S, Klopfleisch R, Hansen W, Buer J, Bruder D, Epple M, Westendorf AM. Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation. Nanomedicine. 2017;13(8):2395–403.", "volume": "13", "year": "2017" }, { "DOI": "10.1007/s13346-017-0426-z", "author": "A Jamali", "doi-asserted-by": "publisher", "first-page": "12", "issue": "1", "journal-title": "Drug Deliv Transl Res", "key": "3520_CR93", "unstructured": "Jamali A, Mottaghitalab F, Abdoli A, Dinarvand M, Esmailie A, Kheiri MT, Atyabi F. Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA. Drug Deliv Transl Res. 2018;8(1):12–20.", "volume": "8", "year": "2018" }, { "DOI": "10.1016/j.vaccine.2011.04.029", "author": "SA Audouy", "doi-asserted-by": "publisher", "first-page": "4345", "issue": "26", "journal-title": "Vaccine", "key": "3520_CR94", "unstructured": "Audouy SA, van der Schaaf G, Hinrichs WL, Frijlink HW, Wilschut J, Huckriede A. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine. 2011;29(26):4345–52.", "volume": "29", "year": "2011" }, { "DOI": "10.1016/j.jconrel.2013.11.013", "author": "HP Patil", "doi-asserted-by": "publisher", "first-page": "51", "journal-title": "J Control Release", "key": "3520_CR95", "unstructured": "Patil HP, Murugappan S, ter Veer W, Meijerhof T, de Haan A, Frijlink HW, Wilschut J, Hinrichs WL, Huckriede A. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. J Control Release. 2014;174:51–62.", "volume": "174", "year": "2014" }, { "DOI": "10.1016/S1473-3099(22)00291-2", "author": "NI Mazur", "doi-asserted-by": "publisher", "first-page": "e2", "issue": "1", "journal-title": "Lancet Infect Dis", "key": "3520_CR96", "unstructured": "Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, Cohen C, Crowe JE, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, Kragten-Tabatabaie L, Lemey P, Libster R, Löwensteyn Y, Mejias A, Munoz FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023;23(1):e2–21.", "volume": "23", "year": "2023" }, { "DOI": "10.1038/srep34108", "author": "AM Killikelly", "doi-asserted-by": "publisher", "first-page": "34108", "journal-title": "Sci Rep", "key": "3520_CR97", "unstructured": "Killikelly AM, Kanekiyo M, Graham BS. Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep. 2016;6:34108.", "volume": "6", "year": "2016" }, { "DOI": "10.1371/journal.ppat.1004757", "author": "CJ Knudson", "doi-asserted-by": "publisher", "first-page": "e1004757", "issue": "3", "journal-title": "PLoS Pathog", "key": "3520_CR98", "unstructured": "Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets. PLoS Pathog. 2015;11(3):e1004757.", "volume": "11", "year": "2015" }, { "DOI": "10.3390/vaccines8040672", "author": "C Biagi", "doi-asserted-by": "publisher", "first-page": "672", "issue": "4", "journal-title": "Vaccines.", "key": "3520_CR99", "unstructured": "Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines. 2020;8(4):672.", "volume": "8", "year": "2020" }, { "DOI": "10.1371/journal.pone.0228572", "author": "X Liu", "doi-asserted-by": "publisher", "first-page": "e0228572", "issue": "2", "journal-title": "PLoS ONE", "key": "3520_CR100", "unstructured": "Liu X, Liang B, Liu X, Amaro-Carambot E, Surman S, Kwong PD, Graham BS, Collins PL, Munir S. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. PLoS ONE. 2020;15(2):e0228572.", "volume": "15", "year": "2020" }, { "DOI": "10.1080/21645515.2020.1779517", "author": "F Scaggs Huang", "doi-asserted-by": "publisher", "first-page": "554", "issue": "2", "journal-title": "Hum Vaccin Immunother", "key": "3520_CR101", "unstructured": "Scaggs Huang F, Bernstein DI, Slobod KS, Portner A, Takimoto T, Russell CJ, Meagher M, Jones BG, Sealy RE, Coleclough C, Branum K, Dickey M, Buschle K, McNeal M, Makowski M, Nakamura A, Hurwitz JL. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum Vaccin Immunother. 2021;17(2):554–9.", "volume": "17", "year": "2021" }, { "DOI": "10.1177/0018578719836646", "author": "L Avery", "doi-asserted-by": "publisher", "first-page": "224", "issue": "4", "journal-title": "Hosp Pharm", "key": "3520_CR102", "unstructured": "Avery L, Hoffmann C, Whalen KM. The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review. Hosp Pharm. 2020;55(4):224–35.", "volume": "55", "year": "2020" }, { "DOI": "10.1093/cid/ciy760", "author": "F Foolad", "doi-asserted-by": "publisher", "first-page": "1641", "issue": "10", "journal-title": "Clin Infect Dis", "key": "3520_CR103", "unstructured": "Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, Chemaly RF. Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2019;68(10):1641–9.", "volume": "68", "year": "2019" }, { "DOI": "10.1111/tid.12844", "author": "TP Trang", "doi-asserted-by": "publisher", "first-page": "e12844", "issue": "2", "journal-title": "Transpl Infect Dis", "key": "3520_CR104", "unstructured": "Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018;20(2):e12844.", "volume": "20", "year": "2018" }, { "DOI": "10.1093/jac/dkt111", "author": "DP Shah", "doi-asserted-by": "publisher", "first-page": "1872", "issue": "8", "journal-title": "J Antimicrob Chemother", "key": "3520_CR105", "unstructured": "Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872–80.", "volume": "68", "year": "2013" }, { "DOI": "10.1093/infdis/jit071", "author": "G Fatkenheuer", "doi-asserted-by": "publisher", "first-page": "1621", "issue": "10", "journal-title": "J Infect Dis", "key": "3520_CR106", "unstructured": "Fatkenheuer G, Gillor D, Platten M, Kochanek M, Salzberger B. Aerosolized ribavirin for patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2013;207(10):1621.", "volume": "207", "year": "2013" }, { "DOI": "10.1093/infdis/jis516", "author": "RF Chemaly", "doi-asserted-by": "publisher", "first-page": "1367", "issue": "9", "journal-title": "J Infect Dis", "key": "3520_CR107", "unstructured": "Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing C, Saifan C, Raad II, Champlin RE. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012;206(9):1367–71.", "volume": "206", "year": "2012" }, { "DOI": "10.1007/s11908-015-0490-9", "author": "K Neemann", "doi-asserted-by": "publisher", "first-page": "490", "issue": "7", "journal-title": "Curr Infect Dis Rep", "key": "3520_CR108", "unstructured": "Neemann K, Freifeld A. Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation. Curr Infect Dis Rep. 2015;17(7):490.", "volume": "17", "year": "2015" }, { "DOI": "10.1182/blood-2010-08-263400", "author": "JN Shah", "doi-asserted-by": "publisher", "first-page": "2755", "issue": "10", "journal-title": "Blood", "key": "3520_CR109", "unstructured": "Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–63.", "volume": "117", "year": "2011" }, { "DOI": "10.1128/AAC.01802-15", "author": "L Detalle", "doi-asserted-by": "publisher", "first-page": "6", "issue": "1", "journal-title": "Antimicrob Agents Chemother", "key": "3520_CR110", "unstructured": "Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016;60(1):6–13.", "volume": "60", "year": "2016" }, { "DOI": "10.1080/19420862.2018.1470727", "author": "A Larios Mora", "doi-asserted-by": "publisher", "first-page": "778", "issue": "5", "journal-title": "MAbs", "key": "3520_CR111", "unstructured": "Larios Mora A, Detalle L, Gallup JM, Van Geelen A, Stohr T, Duprez L, Ackermann MR. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. MAbs. 2018;10(5):778–95.", "volume": "10", "year": "2018" }, { "DOI": "10.1016/S2213-2600(20)30320-9", "author": "S Cunningham", "doi-asserted-by": "publisher", "first-page": "21", "issue": "1", "journal-title": "Lancet Respir Med", "key": "3520_CR112", "unstructured": "Cunningham S, Piedra PA, Martinon-Torres F, Szymanski H, Brackeva B, Dombrecht E, Detalle L, Fleurinck C. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(1):21–32.", "volume": "9", "year": "2021" }, { "DOI": "10.1371/journal.pone.0021823", "author": "DM Lindell", "doi-asserted-by": "publisher", "first-page": "e21823", "issue": "7", "journal-title": "PLoS ONE", "key": "3520_CR113", "unstructured": "Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr, Lukacs NW. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE. 2011;6(7):e21823.", "volume": "6", "year": "2011" }, { "DOI": "10.1080/21645515.2015.1075680", "author": "JJ O'Konek", "doi-asserted-by": "publisher", "first-page": "2904", "issue": "12", "journal-title": "Hum Vaccin Immunother", "key": "3520_CR114", "unstructured": "O’Konek JJ, Makidon PE, Landers JJ, Cao Z, Malinczak CA, Pannu J, Sun J, Bitko V, Ciotti S, Hamouda T, Wojcinski ZW, Lukacs NW, Fattom A, Baker JR Jr. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats. Hum Vaccin Immunother. 2015;11(12):2904–12.", "volume": "11", "year": "2015" }, { "DOI": "10.3390/v7020798", "author": "Z Sun", "doi-asserted-by": "publisher", "first-page": "798", "issue": "2", "journal-title": "Viruses", "key": "3520_CR115", "unstructured": "Sun Z, Wang Q, Jia R, Xia S, Li Y, Liu Q, Xu W, Xu J, Du L, Lu L, Jiang S. Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. Viruses. 2015;7(2):798–819.", "volume": "7", "year": "2015" }, { "DOI": "10.1016/j.vaccine.2021.06.013", "author": "V Ivanov", "doi-asserted-by": "publisher", "first-page": "4063", "issue": "30", "journal-title": "Vaccine", "key": "3520_CR116", "unstructured": "Ivanov V, Oomens AGP, Papin JF, Staats R, Reuter DN, Yu Z, Piedra PA, Wellliver RC Sr. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021;39(30):4063–71.", "volume": "39", "year": "2021" }, { "DOI": "10.1016/j.antiviral.2017.05.005", "author": "YY Jiao", "doi-asserted-by": "publisher", "first-page": "57", "journal-title": "Antiviral Res", "key": "3520_CR117", "unstructured": "Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Antiviral Res. 2017;144:57–69.", "volume": "144", "year": "2017" }, { "DOI": "10.1093/abbs/gmw118", "author": "M Cai", "doi-asserted-by": "publisher", "first-page": "74", "issue": "1", "journal-title": "Acta Biochim Biophys Sin (Shanghai)", "key": "3520_CR118", "unstructured": "Cai M, Wang C, Li Y, Gu H, Sun S, Duan Y, Lai C, Wang K, Yang X, Xing L, Zhang P, Wang Z, Zhang S, Guo X, Liu S, Tong Y, Wang X, Yang P. Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice. Acta Biochim Biophys Sin (Shanghai). 2017;49(1):74–82.", "volume": "49", "year": "2017" }, { "DOI": "10.1080/21645515.2017.1349584", "doi-asserted-by": "crossref", "key": "3520_CR119", "unstructured": "Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus. Hum Vaccin Immunother. 2017;13(12):2894–901." }, { "DOI": "10.1016/j.virol.2016.09.023", "doi-asserted-by": "crossref", "key": "3520_CR120", "unstructured": "Garg R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Virology. 2016;499:288–97." }, { "DOI": "10.1586/14760584.2016.1114418", "author": "CJ Russell", "doi-asserted-by": "publisher", "first-page": "189", "issue": "2", "journal-title": "Expert Rev Vaccines", "key": "3520_CR121", "unstructured": "Russell CJ, Hurwitz JL. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines. 2016;15(2):189–200.", "volume": "15", "year": "2016" }, { "DOI": "10.1016/j.jpeds.2007.02.032", "author": "EA Simoes", "doi-asserted-by": "publisher", "first-page": "34", "issue": "1", "journal-title": "J Pediatr", "key": "3520_CR122", "unstructured": "Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34–42, 42 e31.", "volume": "151", "year": "2007" }, { "DOI": "10.1016/j.vaccine.2014.03.088", "author": "BG Jones", "doi-asserted-by": "publisher", "first-page": "3264", "issue": "26", "journal-title": "Vaccine", "key": "3520_CR123", "unstructured": "Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, Dormitzer PR, DeVincenzo J, Hurwitz JL. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine. 2014;32(26):3264–73.", "volume": "32", "year": "2014" }, { "DOI": "10.1016/j.vaccine.2011.11.046", "author": "BG Jones", "doi-asserted-by": "publisher", "first-page": "959", "issue": "5", "journal-title": "Vaccine", "key": "3520_CR124", "unstructured": "Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine. 2012;30(5):959–68.", "volume": "30", "year": "2012" }, { "DOI": "10.1128/JVI.74.24.11626-11635.2000", "author": "AA Haller", "doi-asserted-by": "publisher", "first-page": "11626", "issue": "24", "journal-title": "J Virol", "key": "3520_CR125", "unstructured": "Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol. 2000;74(24):11626–35.", "volume": "74", "year": "2000" }, { "DOI": "10.1097/INF.0b013e318199c3b1", "author": "M Gomez", "doi-asserted-by": "publisher", "first-page": "655", "issue": "7", "journal-title": "Pediatr Infect Dis J", "key": "3520_CR126", "unstructured": "Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. 2009;28(7):655–8.", "volume": "28", "year": "2009" }, { "DOI": "10.1097/INF.0b013e31823386f1", "author": "DI Bernstein", "doi-asserted-by": "publisher", "first-page": "109", "issue": "2", "journal-title": "Pediatr Infect Dis J", "key": "3520_CR127", "unstructured": "Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012;31(2):109–14.", "volume": "31", "year": "2012" }, { "DOI": "10.1016/j.vaccine.2013.04.015", "author": "CL Nelson", "doi-asserted-by": "publisher", "first-page": "3756", "issue": "36", "journal-title": "Vaccine", "key": "3520_CR128", "unstructured": "Nelson CL, Tang RS, Stillman EA. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells. Vaccine. 2013;31(36):3756–62.", "volume": "31", "year": "2013" }, { "DOI": "10.3389/fimmu.2013.00282", "author": "N Van Braeckel-Budimir", "doi-asserted-by": "crossref", "first-page": "282", "journal-title": "Front Immunol", "key": "3520_CR129", "unstructured": "Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol. 2013;4:282.", "volume": "4", "year": "2013" }, { "DOI": "10.1164/rccm.201810-1921OC", "author": "S Ascough", "doi-asserted-by": "publisher", "first-page": "481", "issue": "4", "journal-title": "Am J Respir Crit Care Med", "key": "3520_CR130", "unstructured": "Ascough S, Vlachantoni I, Kalyan M, Haijema BJ, Wallin-Weber S, Dijkstra-Tiekstra M, Ahmed MS, van Roosmalen M, Grimaldi R, Zhang Q, Leenhouts K, Openshaw PJ, Chiu C. Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2019;200(4):481–92.", "volume": "200", "year": "2019" }, { "DOI": "10.1016/j.healun.2015.08.012", "author": "J Gottlieb", "doi-asserted-by": "publisher", "first-page": "213", "issue": "2", "journal-title": "J Heart Lung Transplant", "key": "3520_CR131", "unstructured": "Gottlieb J, Zamora MR, Hodges T, Musk AW, Sommerwerk U, Dilling D, Arcasoy S, DeVincenzo J, Karsten V, Shah S, Bettencourt BR, Cehelsky J, Nochur S, Gollob J, Vaishnaw A, Simon AR, Glanville AR. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–21.", "volume": "35", "year": "2016" }, { "DOI": "10.1016/j.antiviral.2007.11.009", "author": "J DeVincenzo", "doi-asserted-by": "publisher", "first-page": "225", "issue": "3", "journal-title": "Antiviral Res", "key": "3520_CR132", "unstructured": "DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, Meyers R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008;77(3):225–31.", "volume": "77", "year": "2008" }, { "DOI": "10.1164/rccm.201003-0422OC", "author": "MR Zamora", "doi-asserted-by": "publisher", "first-page": "531", "issue": "4", "journal-title": "Am J Respir Crit Care Med", "key": "3520_CR133", "unstructured": "Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, DeVincenzo J, Vaishnaw A, Cehelsky J, Albert G, Nochur S, Gollob JA, Glanville AR. RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus. Am J Respir Crit Care Med. 2011;183(4):531–8.", "volume": "183", "year": "2011" }, { "DOI": "10.1093/infdis/jiz408", "author": "RA Karron", "doi-asserted-by": "publisher", "first-page": "82", "issue": "1", "journal-title": "J Infect Dis", "key": "3520_CR134", "unstructured": "Karron RA, Luongo C, Mateo JS, Wanionek K, Collins PL, Buchholz UJ. Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children. J Infect Dis. 2020;222(1):82–91.", "volume": "222", "year": "2020" }, { "DOI": "10.1093/infdis/jiy040", "author": "EJ McFarland", "doi-asserted-by": "publisher", "first-page": "1347", "issue": "9", "journal-title": "J Infect Dis", "key": "3520_CR135", "unstructured": "McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2–2 is Highly Immunogenic in Children. J Infect Dis. 2018;217(9):1347–55.", "volume": "217", "year": "2018" }, { "DOI": "10.1093/infdis/jiz603", "author": "EJ McFarland", "doi-asserted-by": "publisher", "first-page": "534", "issue": "4", "journal-title": "J Infect Dis", "key": "3520_CR136", "unstructured": "McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, Collins P, Buchholz UJ. Live Respiratory Syncytial Virus Attenuated by M2–2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. J Infect Dis. 2020;221(4):534–43.", "volume": "221", "year": "2020" }, { "DOI": "10.1093/infdis/jiy066", "author": "UJ Buchholz", "doi-asserted-by": "publisher", "first-page": "1338", "issue": "9", "journal-title": "J Infect Dis", "key": "3520_CR137", "unstructured": "Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA, International Maternal Pediatric Adolescent ACTPST. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children. J Infect Dis. 2018;217(9):1338–46.", "volume": "217", "year": "2018" }, { "DOI": "10.1126/scitranslmed.aac8463", "author": "RA Karron", "doi-asserted-by": "publisher", "first-page": "312ra175", "issue": "312", "journal-title": "Sci Trans Med", "key": "3520_CR138", "unstructured": "Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, Buchholz UJ. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Trans Med. 2015;7(312):312ra175.", "volume": "7", "year": "2015" }, { "DOI": "10.1093/infdis/jiaa049", "author": "EJ McFarland", "doi-asserted-by": "publisher", "first-page": "2050", "issue": "12", "journal-title": "J Infect Dis", "key": "3520_CR139", "unstructured": "McFarland EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Cielo M, Wiznia A, Deville JG, Yang L, Luongo C, Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2–2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children. J Infect Dis. 2020;221(12):2050–9.", "volume": "221", "year": "2020" }, { "DOI": "10.1136/bmjopen-2015-008748", "author": "CA Green", "doi-asserted-by": "publisher", "first-page": "e008748", "issue": "10", "journal-title": "BMJ Open", "key": "3520_CR140", "unstructured": "Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese R, Thompson AJ, Sande CS, de Lara C, Klenerman P, Pollard AJ. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2–1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open. 2015;5(10):e008748.", "volume": "5", "year": "2015" }, { "DOI": "10.1126/scitranslmed.aac5745", "author": "CA Green", "doi-asserted-by": "publisher", "first-page": "300ra126", "issue": "300", "journal-title": "Sci Trans Med", "key": "3520_CR141", "unstructured": "Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Trans Med. 2015;7(300):300ra126.", "volume": "7", "year": "2015" }, { "DOI": "10.1016/j.jinf.2019.02.003", "author": "CA Green", "doi-asserted-by": "publisher", "first-page": "382", "issue": "5", "journal-title": "J Infect", "key": "3520_CR142", "unstructured": "Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, Silva-Reyes L, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Hutchings CL, Cargill T, Angus B, Klenerman P, Pollard AJ. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. J Infect. 2019;78(5):382–92.", "volume": "78", "year": "2019" }, { "DOI": "10.1124/dmd.122.000934", "author": "ER McColl", "doi-asserted-by": "publisher", "first-page": "130", "issue": "1", "journal-title": "Drug Metab Dispos", "key": "3520_CR143", "unstructured": "McColl ER, Croyle MA, Zamboni WC, Honer WG, Heise M, Piquette-Miller M, Goralski KB. COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics. Drug Metab Dispos. 2023;51(1):130–41.", "volume": "51", "year": "2023" } ], "reference-count": 143, "references-count": 143, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s11095-023-03520-1" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology (medical)", "Organic Chemistry", "Pharmaceutical Science", "Pharmacology", "Molecular Medicine", "Biotechnology" ], "subtitle": [], "title": "Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }